Drug intelligence / Profile preview

CTX-2026

Development stage: Discontinued
Lead developer: Compass Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

CTX-2026 is an investigational **fully human monoclonal antibody** developed by Compass Therapeutics that binds **butyrophilin subfamily 3 member A1** and functions as a **BTN3A1 inhibitor**. It was being explored as an **anticancer immunotherapy** and has shown anti-tumor activity in ovarian tumor models in preclinical research. Based on the provided sources, the program's highest global R&D status is **discontinued** and no marketed brand name has been identified.

Targets

BTN3A1 (Butyrophilin subfamily 3 member A1)

Beyond the preview

Go deeper on CTX-2026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX-2026.

Explore the full profile